Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation

Background/Aim: Systemic lupus erythematosus‑associated pulmonary arterial hypertension (SLE‑PAH) is a severe complication marked by elevated pulmonary artery pressure, leading to exertional dyspnea and right‑sided heart failure. Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches. This aim of this study was to investigate the efficacy of molecular hydrogen therapy in a patient with SLE‑PAH with decompensated right‑side heart failure. Case Report: We present the case of a 51‑year‑old female diagnosed with SLE‑PAH in 2012. Despite treatment with vasodilator agents, her condition worsened following an episode of sepsis, leading to severe dyspnea and oxygen desaturation since 2018. In March 2024, molecular hydrogen therapy was introduced as an adjuvant treatment. The patient received daily hydrogen capsules, which resulted in an increased percentage of Tr1 cells, and a decreased percentage of Treg cell subsets, B cell subsets, marginal cell, and plasma cell. Her clinical symptoms stabilized, and no adverse effects or complications were observed. Conclusion: This case study highlights the potential efficacy of molecular hydrogen therapy in a patient with SLE‑ PAD and decompensated right‑sided heart failure precipitated by sepsis. Further research is needed to confirm its therapeutic benefits, particularly its ability to modulate immune markers and improve clinical outcomes.